Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors

Journal of Neural Transmission

Volumn 122, Issue 1, 2015, Pages 35-42

  Gressier, F ^a   Verstuyft, C ^b   Hardy, P ^a   Becquemont, L ^b   Corruble, E ^a  

^a Universite Paris Sud   (France)

^b BICÊTRE HOSPITAL   (France)

Author keywords

Antidepressant response; Comedications; CYP2D6 genotype; CYP2D6 inhibitors; CYP2D6 phenotype; Depression

Indexed keywords

ACAMPROSATE; ALIMEMAZINE; ALPRAZOLAM; AMISULPRIDE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BROMAZEPAM; BUPRENORPHINE; CHLORPROMAZINE; CLOMIPRAMINE; CLONAZEPAM; CLORAZEPATE; CYAMEMAZINE; CYTOCHROME P450 2D6; CYTOCHROME P450 INHIBITOR; DOSULEPIN; FLUOXETINE; IMIPRAMINE; LORMETAZEPAM; MIANSERIN; MIRTAZAPINE; OLANZAPINE; OXAZEPAM; PAROXETINE; PRAZEPAM; RISPERIDONE; UNINDEXED DRUG; VENLAFAXINE; ZOLPIDEM; ZOPICLONE; ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2D6 INHIBITORS; PSYCHOTROPIC DRUGS;

ADULT; ALLELISM; ARTICLE; DRUG EFFICACY; ENZYME SUBSTRATE; FEMALE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIDDLE AGED; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT RESPONSE; ANALYSIS OF VARIANCE; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; GENETICS; GENOTYPE; HUMANS; PHARMACOGENETICS; PHENOTYPE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2D6 INHIBITORS; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; PHENOTYPE; PROSPECTIVE STUDIES; PSYCHOTROPIC DRUGS; TREATMENT OUTCOME;

EID: 84921741532     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-014-1273-4     Document Type: Article

References (42)

1. Allorge D, Beaune PH, Becquemont L, Bessard G, Bezieau S, Boisdron-Celle M, Boyer JC, Broly F, Dhaneens CM, Fonrose X, Gagnieu MC, Gamelin E, Gozé C, Jacqz-Aigrain E, Loric S, Loriot MA, Marquet P, Morel A, Namour B, Paintaud G, Peoc’h K, Picard N, Watier H, Verstuyft C (2007) Molecular pharmacogenetics in hospital laboratories in France: current data and future prospects. Ann Pharm Fr 65:371–381
2. Becquemont L, Alfirevic A, Amstutz U, Brauch H, Jacqz-Aigrain E, Laurent-Puig P, Molina MA, Niemi M, Schwab M, Somogyi AA, Thervet E, Maitland-van der Zee AH, van Kuilenburg AB, van Schaik RH, Verstuyft C, Wadelius M, Daly AK (2011) Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB conference on pharmacogenetics and pharmacogenomics. Pharmacogenomics 12:113–124. doi:10.2217/pgs.10.147
3. Bertilsson L, Dahl ML, Dalén P, Al-Shurbaji A (2002) Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53:111–122
4. Borges S, Desta Z, Jin Y, Faouzi A, Robarge JD, Philips S, Nguyen A, Stearns V, Hayes D, Rae JM, Skaar TC, Flockhart DA, Li L (2010) Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol 50:450–458. doi:10.1177/0091270009359182
5. Chou WH, Yan FX, de Leon J, Barnhill J, Rogers T, Cronin M, Pho M, Xiao V, Ryder TB, Liu WW, Teiling C, Wedlund PJ (2000) Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 20:246–251. doi:10.1097/00004714-200004000-00019
6. de Leon J, Susce MT, Murray-Carmichael E (2006) The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol Diagn Ther 10:135–151. doi:10.1007/BF03256453
7. Flockhart DA (2007) Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine. http://medicine.iupui.edu/clinpharm/ddis/clinical-table/. Accessed 5 May 2014
8. Funck-Brentano C, Boëlle PY, Verstuyft C, Bornert C, Becquemont L, Poirier JM (2005) Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. Eur J Clin Pharmacol 61:821–829
9. Gerstenberg G, Aoshima T, Fukasawa T, Yoshida K, Takahashi H, Higuchi H, Murata Y, Shimoyama R, Ohkubo T, Shimizu T, Otani K (2003) Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology 167:443–448
10. Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry JM, Bondolfi G, Bertschy G (2008) CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit 30:474–482
11. Grasmader K, Verwohlt PL, Rietschel M, Dragicevic A, Muller M, Hiemke C, Freymann N, Zobel A, Maier W, Rao ML (2004) Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 60:329–336. doi:10.1007/s00228-004-0766-8
12. Gressier F, Bouaziz E, Verstuyft C, Hardy P, Becquemont L, Corruble E (2009) 5-HTTLPR modulates antidepressant efficacy in depressed women. Psychiatr Genet 19:195–200. doi:10.1097/YPG.0b013e32832cef0d
13. Guy W (1976) Clinical global impressions. In: Guy W (ed) ECDEU assessment manual for psychopharmacology, revised. US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, pp 218–222
14. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62. doi:10.1136/jnnp.23.1.56
15. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, Skaar TC, Muller DJ, Gaedigk A, Stingl JC (2013) Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 93:402–408. doi:10.1038/clpt.2013.2
16. Hodgson K, Tansey K, Dernovsek MZ, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D, Smith R, Craig IW, Farmer AE, Aitchison KJ, Belsy S, Davis OS, Uher R, McGuffin P (2014) Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. J Psychopharmacol 28:133–141. doi:10.1177/0269881113512041
17. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496–526. doi:10.1177/0269881113512041
18. James HM, Coller JK, Gillis D, Bahnisch J, Sallustio BC, Somogyi AA (2004) A new simple diagnostic assay for the identification of the major CYP2D6 genotypes by DNA sequencing analysis. Int J Clin Pharmacol Ther 42:719–723. doi:10.5414/CPP42719
19. Kawanishi C, Lundgren S, Agren H, Bertilsson L (2004) Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 59:803–807. doi:10.1007/s00228-003-0701-4
20. Kirchheiner J, Rodriguez-Antona C (2009) Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders. CNS Drugs 23:181–191. doi:10.2165/00023210-200923030-00001
21. Lobello KW, Preskorn SH, Guico-Pabia CJ, Jiang Q, Paul J, Nichols AI, Patroneva A, Ninan PT (2010) Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry 71:1482–1487. doi:10.4088/JCP.08m04773blu
22. Mrazek DA (2010) Psychiatric pharmacogenomics. Oxford University Press, New York. ISBN 0195367294
23. Mrazek DA, Biernacka JM, O’Kane DJ, Black JL, Cunningham JM, Drews MS, Snyder KA, Stevens SR, Rush AJ, Weinshilboum RM (2011) CYP2C19 variation and citalopram response. Pharmacogenet Genomics 21:1–9. doi:10.1097/FPC.0b013e328340bc5a
24. Murphy GM Jr, Kremer C, Rodrigues HE, Schatzberg AF (2003) Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 160:1830–1835. doi:10.1176/appi.ajp.160.10.1830
25. Ohara K, Tanabu S, Ishibashi K, Ikemoto K, Yoshida K, Shibuya H (2003) CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects. Eur J Clin Pharmacol 58:659–661
26. Peters EJ, Slager SL, Kraft JB, Jenkins GD, Reinalda MS, McGrath PJ, Hamilton SP (2008) Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One 3:e1872
27. Preskorn SH, Kane CP, Lobello K, Nichols AI, Fayyad R, Buckley G, Focht K, Guico-Pabia CJ (2013) Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. J Clin Psychiatry 74:614–621. doi:10.4088/JCP.12m07807
28. Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J, Lanczik M, Eschenhagen T (2004) CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther 75:386–393. doi:10.1016/j.clpt.2003.12.015
29. Roberts RL, Kennedy MA (2006) Rapid detection of common cytochrome P450 2D6 alleles in Caucasians. Clin Chim Acta 366:348–351
30. Roberts RL, Mulder RT, Joyce PR, Luty SE, Kennedy MA (2004) No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Hum Psychopharmacol 19:17–23. doi:10.1002/hup.539
31. Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA (2013) Applications of CYP450 testing in the clinical setting. Mol Diagn Ther 17:165–184. doi:10.1007/s40291-013-0028-5
32. Schaeffeler E, Schwab M, Eichelbaum M, Zanger UM (2003) CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum Mutat 22:476–485. doi:10.1002/humu.10280
33. Schenk PW, van Fessem MA, Verploegh-Van Rij S, Mathot RA, van Gelder T, Vulto AG, van Vliet M, Lindemans J, Bruijn JA, van Schaik RH (2008) Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Mol Psychiatry 13:597–605. doi:10.1038/sj.mp.4002057
34. Serretti A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y, Sens-Espel R, Bollen J, Zohar J, Berlo J, Lienard P, De Ronchi D, Mendlewicz J, Souery D (2009) Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. Int Clin Psychopharmacol 24:250–256. doi:10.1097/YIC.0b013e32832e5b0d
35. Shah RR, Shah DR (2012) Personalized medicine: is it a pharmacogenetic mirage? Br J Clin Pharmacol 74:698–721. doi:10.1111/j.1365-2125.2012.04328.x
36. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(suppl 20):22–33
37. Steimer W, Zopf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, Messner B, Kissling W, Leucht S (2005) Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 51:376–385. doi:10.1373/clinchem.2004.041327
38. Suzuki Y, Sawamura K, Someya T (2006) Polymorphisms in the 5-hydroxytryptamine 2A receptor and Cytochrome P4502D6 genes synergistically predict fluvoxamine-induced side effects in Japanese depressed patients. Neuropsychopharmacology 31:825–831
39. Tsai MH, Lin KM, Hsiao MC, Shen WW, Lu ML, Tang HS, Fang CK, Wu CS, Lu SC, Liu SC, Chen CY, Liu YL (2010) Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics 11:537–546. doi:10.2217/pgs.09.168
40. Vandel P, Haffen E, Nezelof S, Broly F, Kantelip JP, Sechter D (2004) Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients. Hum Psychopharmacol 19:293–298. doi:10.1002/hup.598
41. Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–141. doi:10.1016/j.pharmthera.2012.12.007
42. Zourková A, Hadasová E (2003) Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurrence of adverse effects. Gen Physiol Biophys 22:103–113